When an Old Study Casted Doubt on Drug, Arbor Pharma Turned to Trump Nominee Tom Price for Help
1/20/2017 6:26:32 AM
The $3 pill known as BiDil was already a difficult sell when a Georgia-based pharmaceutical company bought the marketing rights a few years ago. A treatment for African Americans suffering from heart failure, BiDil had never really caught on, forcing the drug company that developed it to take a buyout offer. One strike against the drug was a 2009 study that raised questions about its safety and effectiveness.
comments powered by